CervoMed Inc. announced it will present deeper insights highlighting the neflamapimod clinical development program, including findings in phase2a that led to the final Phase 2b study design for the treatment of patients with dementia with Lewy bodies (DLB), in an oral presentation at the 16(th) Clinical Trials in Alzheimer's Disease (CTAD) conference, being held October 24-27, 2023, in Boston, Massachusetts. Details for the CTAD 2023 Oral Presentation Title: A Phase 2b Clinical Trial of Neflamapimod in Dementia with Lewy Bodies Designed to Confirm the Efficacy Results from Phase 2a Date /Time: October 25, 2023 /2:50 p.m. ET Presenter: Niels Prins, MD, PhD, Chief Executive Officer of Brain Research Center - Amsterdam Session Title: OC8 - ORAL COMMUNICATIONS.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.9 USD | -2.01% | -0.99% | +213.24% |
Apr. 08 | Canaccord Genuity Adjusts Price Target on CervoMed to $65 From $50, Maintains Buy Rating | MT |
Mar. 29 | CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+213.24% | 201M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- CRVO Stock
- News CervoMed Inc.
- CervoMed Inc. Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies